Related Experiment Video
Updated: Aug 15, 2026
14:14
Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Serum (circulating) tumor markers for breast cancer
1Breast Evaluation Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Summary
Several circulating tumor markers show promise for breast cancer management, including CA15-3, CEA, and novel markers. Further research is needed to confirm their clinical utility and avoid redundant testing.
Area of Science:
- Oncology
- Biomarkers
- Cancer Diagnostics
Background:
- Circulating markers are crucial for breast cancer identification, screening, prognosis, detection, and monitoring.
- Established markers like CA15-3 and CEA indicate clinical course.
- Novel markers including BrCa1, anti-p53, anti-HER-2/neu, angiogenesis indicators, and HER-2/neu extracellular domain show potential.
Purpose of the Study:
- To evaluate the clinical utility of various circulating markers for breast cancer.
- To determine the independence of markers to prevent redundant testing and associated costs.
- To inform clinicians about marker limitations in sensitivity and specificity.
Main Methods:
- Review and analysis of existing circulating markers for breast cancer.
- Assessment of marker potential for identification, screening, prognosis, detection, and monitoring.
- Evaluation of marker independence and clinical performance characteristics.
Main Results:
- CA15-3 and CEA are promising for indicating breast cancer clinical course.
- Novel markers like BrCa1, anti-p53, and HER-2/neu related markers warrant further investigation.
- Precise clinical utilities and independence of markers require further determination.
Conclusions:
- Several circulating markers show promise for breast cancer management.
- Determining marker independence and understanding limitations are critical for accurate clinical interpretation.
- Further research is essential to establish the definitive roles of these markers in clinical practice.
